~~<i id='CD37E9BC8F'><strike id='CD37E9BC8F'><tt id='CD37E9BC8F'><pre id='CD37E9BC8F'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

explore

hotspot

author：knowledge 2025-08-12 09:09:46 - browse：81

Blue nerve cell surrounded by red antibodies. -- health coverage from STAT — Adobe

Belgian drugmaker Argenx said Monday that its antibody treatment called Vyvgart significantly delayed the progression of an autoimmune nerve disorder that causes people to lose feeling and muscle strength in the arms and legs.

The positive outcome — a 61% reduction in the risk of relapse compared to a placebo — achieved the main goal of a Phase 3 clinical trial designed to demonstrate Vyvgart’s benefit for patients with chronic inflammatory demyelinating polyneuropathy, or CIDP.

“We hit the bullseye,” said Argenx CEO Tim Van Hauwermeiren.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Hepatitis C has a cure — but many Americans still lack access to it
Next article： Biden’s NIH nominee is languishing in Congress

hotspot

Wikipedia

knowledge

leisure time

entertainment

hotspot

HouseEnergyandCommerceCommitteeChairCathyMcMorrisRodgers(R-Wash).J.ScottApplewhite/APWASHINGTON—TheH

WSS

Hospital price transparency does save money, advocate argues

‘Insidious 5’ topples 'Indiana Jones' before ‘Mission: Impossible’ launches

Recent heat wave in the Mediterranean caused by climate change: Study

FDA struggles to regulate food additives, sometimes for decades

Researchers explore possible ties between long Covid, menopause

Pandemic and All Hazards Preparedness Act needs lean update

explore

hotspot

hotspot

The high cost of giving birth even with insurance

STAT Summit: Michael J. Fox on progress in Parkinson's research

Continuity nursing helped my family in our darkest PICU moments

Impact of Dobbs ruling felt at reproductive medicine meeting

Hepatitis C has a cure — but many Americans still lack access to it

FDA struggles to regulate food additives, sometimes for decades

Medicare details structure of new drug price negotiation program

How climate

Apple is now the first public company to be valued at $3 trillion

Bank of America ordered to pay more than $100 million for double charging fees, withholding rewards

Wikipedia

‘Insidious 5’ topples 'Indiana Jones' before ‘Mission: Impossible’ launches

Biden targets hefty hospital 'facility fees' that often surprise patients

DeSantis defends odds vs. Trump, despite early poll gap: 'We've worked really hard'

Studies point to risks of excluding people with obesity from drug trials

STAT Summit: How a Chicago ER doctor tackles gun violence

Medicare reduced heart disease by changing how it pays doctors

knowledge

leisure time

entertainment

hotspot